Tor Arne Hagve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tor Arne Hagve has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Anja Mehlum
Biotechnology Centre of Oslo, University of Oslo and the Department of Comparative Medicine, National Hospital, Norway
1 shared publicationAnke Neukamm
Division of Medicine, Akershus University Hospital, Lørenskog, Norway
1 shared publication- Arne Didrik Høiseth
A Division of Medicine , Akershus University Hospital , Lørenskog , Norway
1 shared publication Elisabeth Gjernes
Biotechnology Centre of Oslo, University of Oslo and the Department of Comparative Medicine, National Hospital, Oslo
1 shared publicationHans Prydz
Biotechnology Centre of Oslo, University of Oslo and the Department of Comparative Medicine, National Hospital, Oslo
1 shared publicationLars Aage Solberg
Laboratory of Pathology, Oslo City Hospital, Oslo
1 shared publication
Latest Publications
- Open Access
- 16 January 2014
- Published by BMJ in Open Heart
- Vol. 1 (1) , e000001
The clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations ofchronic obstructive pulmonary disease
Objective: To assess the prevalence and long-term prognostic value of a dynamic (rise/fall) pattern of cardiac troponin T (hs-cTnT) elevation during acute exacerbation of chronic obstructive pulmonary disease (AECOPD) compared with a stable hs-cTnT elevation. Methods: Prospective cohort study of unselected patients admitted with AECOPD to the emergency room of a university hospital. Serial hs-cTnT measurements were made during admission. Survival after a median of 1.8 years was recorded. Results: 83 patients with a mean age of 72 years and a mean forced expiratory volume in 1 s (FEV1) of 0.9 L. The mortality rate was 62%. The median hs-cTnT at admission was 27 ng/L (IQR 13.4–51)). 65 patients (78%) had at least one hs-cTnT measurement ≥14 ng/L, and among these the median change in hs-cTnT was 50.7% (IQR 25.2–89.4). Of the patients with serial hs-cTnT measurements, 53 (82%) had a dynamic pattern (ie, ΔTnT ≥20%). In multivariate analysis, stable hs-cTnT elevation was associated with increasing age (OR per 5 years with 95% CI 1.9 (1.01 to 3.7), p=0.045) and low Hb (OR 7.3 (1.1 to 49), p=0.039). Stable hs-cTnT elevation was associated with increased mortality with an HR of 2.4 (95%CI 1.1 to 5.3, p=0.027) in the multivariate Cox regression analysis. Conclusions: Among the patients with at least one hs-cTnT above the 99th centile, 82% had a rise/fall pattern, as requested to make a diagnosis of myocardial infarction. Compared to a dynamic rise/fall pattern of hs-cTnT, a stable and moderately elevated hs-cTnT during AECOPD is associated with poor long-term prognosis.
- 16 January 2014
- Published by BMJ in Open Heart
- Vol. 1 (1) , e000001
Open AccessThe clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations ofchronic obstructive pulmonary disease
Objective: To assess the prevalence and long-term prognostic value of a dynamic (rise/fall) pattern of cardiac troponin T (hs-cTnT) elevation during acute exacerbation of chronic obstructive pulmonary disease (AECOPD) compared with a stable hs-cTnT elevation. Methods: Prospective cohort study of unselected patients admitted with AECOPD to the emergency room of a university hospital. Serial hs-cTnT measurements were made during admission. Survival after a median of 1.8 years was recorded. Results: 83 patients with a mean age of 72 years and a mean forced expiratory volume in 1 s (FEV1) of 0.9 L. The mortality rate was 62%. The median hs-cTnT at admission was 27 ng/L (IQR 13.4–51)). 65 patients (78%) had at least one hs-cTnT measurement ≥14 ng/L, and among these the median change in hs-cTnT was 50.7% (IQR 25.2–89.4). Of the patients with serial hs-cTnT measurements, 53 (82%) had a dynamic pattern (ie, ΔTnT ≥20%). In multivariate analysis, stable hs-cTnT elevation was associated with increasing age (OR per 5 years with 95% CI 1.9 (1.01 to 3.7), p=0.045) and low Hb (OR 7.3 (1.1 to 49), p=0.039). Stable hs-cTnT elevation was associated with increased mortality with an HR of 2.4 (95%CI 1.1 to 5.3, p=0.027) in the multivariate Cox regression analysis. Conclusions: Among the patients with at least one hs-cTnT above the 99th centile, 82% had a rise/fall pattern, as requested to make a diagnosis of myocardial infarction. Compared to a dynamic rise/fall pattern of hs-cTnT, a stable and moderately elevated hs-cTnT during AECOPD is associated with poor long-term prognosis.
Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet‐induced atherosclerosisNote
Human lecithin:cholesterol acyltransferase (LCAT) is a key enzyme in the metabolism of cholesterol. We have used homozygous transgenic mice overexpressing the human LCAT transgene to study the effect of a “Western‐type” atherogenic diet (30% fat, 5% cholesterol and 2% cholic acid) on their LCAT expression, activity, lipoprotein profile and tendency to develop atherosclerosis. The LCAT activity was 35‐fold higher in serum of the homozygous transgenic mice than in murine control serum, and decreased 11–20% in the transgenic mice when fed the atherogenic diet. The total cholesterol and high‐density lipoprotein cholesterol (HDL‐C) concentrations were approximately doubled in the transgenic mice compared with the controls when both groups were fed a regular chow diet. In mice on the atherogenic diet, the triglyceride concentration decreased about 50% to the same level in transgenic and control mice. Total cholesterol and HDL‐C concentrations increased and were 60–80% higher in the transgenic mice. The expression of LCAT mRNA in the liver was decreased by 49–60% in the transgenic mice when fed the atherogenic diet. The development of atherosclerosis was similar in transgenic and control mice. Thus, the 14‐ to 27‐fold higher LCAT activity and the higher HDL‐C concentrations in the homozygous LCAT transgenic mice had no significant protective influence on the development of diet‐induced atherosclerosis.
Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet‐induced atherosclerosisNote
Human lecithin:cholesterol acyltransferase (LCAT) is a key enzyme in the metabolism of cholesterol. We have used homozygous transgenic mice overexpressing the human LCAT transgene to study the effect of a “Western‐type” atherogenic diet (30% fat, 5% cholesterol and 2% cholic acid) on their LCAT expression, activity, lipoprotein profile and tendency to develop atherosclerosis. The LCAT activity was 35‐fold higher in serum of the homozygous transgenic mice than in murine control serum, and decreased 11–20% in the transgenic mice when fed the atherogenic diet. The total cholesterol and high‐density lipoprotein cholesterol (HDL‐C) concentrations were approximately doubled in the transgenic mice compared with the controls when both groups were fed a regular chow diet. In mice on the atherogenic diet, the triglyceride concentration decreased about 50% to the same level in transgenic and control mice. Total cholesterol and HDL‐C concentrations increased and were 60–80% higher in the transgenic mice. The expression of LCAT mRNA in the liver was decreased by 49–60% in the transgenic mice when fed the atherogenic diet. The development of atherosclerosis was similar in transgenic and control mice. Thus, the 14‐ to 27‐fold higher LCAT activity and the higher HDL‐C concentrations in the homozygous LCAT transgenic mice had no significant protective influence on the development of diet‐induced atherosclerosis.